Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from GlycoMimetics ( (GLYC) ).
On February 19, 2025, GlycoMimetics received a termination notice from Apollomics, ending their Collaboration and License Agreement effective January 2, 2020, which granted Apollomics rights to develop and commercialize uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau, and Taiwan. This termination, effective 90 days post-notice, relieves GlycoMimetics of any material obligations under the agreement. Additionally, on February 21, 2025, several directors, including the CEO and CFO, resigned from GlycoMimetics’ Board, with the CEO and CFO entering into separation and consulting agreements. These changes indicate a significant shift in the company’s leadership structure.
More about GlycoMimetics
GlycoMimetics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of novel glycomimetic drugs to address unmet medical needs. The company’s primary products include uproleselan and GMI-1687, which were licensed for development and commercialization in specific Asian markets.
YTD Price Performance: 9.80%
Average Trading Volume: 1,632,790
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.1M
For a thorough assessment of GLYC stock, go to TipRanks’ Stock Analysis page.